TY - JOUR
T1 - The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception
AU - Atrio, Jessica
AU - Stek, Alice
AU - Vora, Hita
AU - Sanchez-Keeland, Lorraine
AU - Zannat, Ferdous
AU - Natavio, Melissa
N1 - Publisher Copyright:
© 2014 The European Society of Contraception and Reproductive Health.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Objective: To compare cervical mucus score (CMS) with and without protease inhibitors (PI) before and after taking norethindrone (NET). Study design: This two-arm, researcher blinded, non-randomised, prospective study was conducted to evaluate cervical mucus quality in HIV-positive women taking progestin only pills. The study group was taking a PI, and compared to women taking ARV regimens that have demonstrated no significant interaction with NET in prior pharmacokinetic trials with combined oral contraceptives. The women had a cervical mucus score prior to NET administration. Mucus Scoring was repeated after 21 days of steady state exposure to oral NET 0.35 milligrams. Cervical mucus quality was quantified according to the World Health Organisation criteria, which include: volume, consistency, cellularity, spinnbarkeit, and ferning. Results: Sixteen women took PI and 17 were controls. Baseline CMS were similar (p ≥ 0.1). After 21 days CMS were similar among the two groups (p = 1). Conclusions: HIV-positive women taking PI demonstrated thickened cervical mucus with oral norethindrone 0.35 mg and are similar to HIV-positive women taking no PI therapy. This may suggest no difference in contraceptive efficacy of progestin only pills in HIV-positive women taking PI.
AB - Objective: To compare cervical mucus score (CMS) with and without protease inhibitors (PI) before and after taking norethindrone (NET). Study design: This two-arm, researcher blinded, non-randomised, prospective study was conducted to evaluate cervical mucus quality in HIV-positive women taking progestin only pills. The study group was taking a PI, and compared to women taking ARV regimens that have demonstrated no significant interaction with NET in prior pharmacokinetic trials with combined oral contraceptives. The women had a cervical mucus score prior to NET administration. Mucus Scoring was repeated after 21 days of steady state exposure to oral NET 0.35 milligrams. Cervical mucus quality was quantified according to the World Health Organisation criteria, which include: volume, consistency, cellularity, spinnbarkeit, and ferning. Results: Sixteen women took PI and 17 were controls. Baseline CMS were similar (p ≥ 0.1). After 21 days CMS were similar among the two groups (p = 1). Conclusions: HIV-positive women taking PI demonstrated thickened cervical mucus with oral norethindrone 0.35 mg and are similar to HIV-positive women taking no PI therapy. This may suggest no difference in contraceptive efficacy of progestin only pills in HIV-positive women taking PI.
KW - AIDS
KW - antiretroviral medication
KW - contraceptive efficacy
KW - drug interaction
KW - hormonal contraception
KW - progestin only pills
UR - http://www.scopus.com/inward/record.url?scp=84924956640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924956640&partnerID=8YFLogxK
U2 - 10.3109/13625187.2014.957826
DO - 10.3109/13625187.2014.957826
M3 - Article
C2 - 25285572
AN - SCOPUS:84924956640
SN - 1362-5187
VL - 20
SP - 149
EP - 153
JO - European Journal of Contraception and Reproductive Health Care
JF - European Journal of Contraception and Reproductive Health Care
IS - 2
ER -